Omega-3 Supplementation and Attention-deficit-hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dietary Supplement: omega-3 fatty acid alpha-linolenic acid (ALA)Dietary Supplement: Placebo
- Registration Number
- NCT00874536
- Lead Sponsor
- Hadassah Medical Organization
- Brief Summary
It is assumed that only 1/5 of children diagnosed with attention-deficit-hyperactivity disorder (ADHD) are treated. New treatment modalities are urgently needed. Omega-3 fatty acids have been used in this setting, yet results are conflicting. The parent omega-3 fatty acid alpha-linolenic acid (ALA) has only been used in one trial. 40 children diagnosed with ADHD will be randomized to consume either ALA or placebo for two months. Baseline and end assessments will include ADHD-related questionnaires and a computerized test. The investigators hypothesize that ALA supplementation will prove beneficial for children with ADHD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- ADHD diagnosis
- informed consent
- refusal of any testing
- any comorbidities
- any medication or supplement use
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ALA omega-3 fatty acid alpha-linolenic acid (ALA) This group will receive the ALA supplement Placebo Placebo This group will receive the placebo supplement
- Primary Outcome Measures
Name Time Method ADHD symptoms 8 weeks scores of DSM and Conners questionnaires
- Secondary Outcome Measures
Name Time Method Computerized test performance 8 weeks performance in a computerized test of attention
Trial Locations
- Locations (1)
Hadassah Medical Organization
🇮🇱Jerusalem, Israel